NCT06218303 2026-03-12
Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ
University of Pittsburgh
Phase 1 Recruiting
Clinical Trials
19 trialsNCT05700006 2026-03-05
BETA
University of Michigan
Completed
NCT05879926 2026-03-03
OFSET
NRG Oncology
Phase 3 Recruiting
NCT02767661 2026-02-27
MECCA
Sun Yat-sen University
Phase 3 Completed
NCT07423611 2026-02-20
RACE
Fudan University
Phase 2 Not yet recruiting
NCT07400523 2026-02-10
Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3 Not yet recruiting
NCT06534125 2026-01-29
Acutherapy to Prevent Aromatase Inhibitor-Associated Arthralgias in Non-Hispanic Black Postmenopausal Women With Early-Stage Breast Cancer
Emory University
Phase NA Recruiting
NCT06970912 2026-01-21
DNADalHR
Peking University People's Hospital
Phase 2 Recruiting
NCT05826964 2026-01-13
Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer
University of Miami
Phase 2 Active not recruiting
NCT04762979 2026-01-02
Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer
Big Ten Cancer Research Consortium
Phase 2 Active not recruiting
NCT06107673 2025-12-11
Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC）
Hebei Medical University Fourth Hospital
Phase 2 Recruiting
NCT03079011 2025-11-18
PADA-1
UNICANCER
Phase 3 Completed
NCT03959891 2025-09-29
AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)
Massachusetts General Hospital
Phase 1 Active not recruiting
NCT04227327 2025-07-29
HERMIONE-7
University of Milano Bicocca
Phase 2 Terminated
NCT04352777 2025-07-20
Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer
Duke University
Phase 2 Completed
NCT06996093 2025-05-30
Chemotherapy Omission in HR-positive/HER2-negative Breast Cancer With Lymph Node Negative Disease Receiving Adjuvant Endocrine Therapy and CDK4/6 Inhibitor
Fudan University
Phase 3 Not yet recruiting
NCT05362760 2025-05-16
MINERVA
University of Ulm
Phase 4 Recruiting
NCT05190094 2025-05-07
ICRG0201
International Cancer Research Group, United Arab Emirates
Phase 2 Recruiting
NCT02040857 2025-04-29
Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Completed